Biotechnology company Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported on Friday the receipt of Health Canada's marketing authorisation for the prescription medicine TRIKAFTA for the treatment of cystic fibrosis (CF) in people ages 12 years and older.
Cystic fibrosis (CF), a rare, life-shortening genetic disease affecting more than 80,000 people globally, is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract.
Health Canada has approved TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation.
For the first time, approximately 1,100 eligible patients with CF ages 12 years and older who have at least one F508del mutation have a medicine that targets the underlying cause of their CF. TRIKAFTA is designed to increase the quantity and function of the F508del-CFTR protein at the cell surface, added the company.
Additionally, TRIKAFTA's approval was supported by positive results of three global Phase 3 studies in people ages 12 years and older with CF: a 24-week Phase 3 study in 403 people with one F508del mutation and one minimal function mutation (F/MF), a four-week Phase 3 study in 107 people with two F508del mutations (F/F) and a Phase 3 study in 258 people heterozygous for the F508del-CFTR mutation and a CFTR gating mutation (F/G) or a residual function mutation (F/RF), concluded the company.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera